

# GelTex Pharmaceuticals Incorporated

[View the current GelTex Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/4323-GelTex+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/bioporporate/4323-GelTex+Pharmaceuticals+Incorporated.html>)

## Contact Details:

9 Fourth Avenue

Waltham

MA

02451

United States of America

Tel: 781 290 5888

Fax: 617 290 5890

Email:

GelTex Pharmaceuticals, Inc. is developing non-absorbed, polymer-based pharmaceuticals that selectively bind to and eliminate target substances from the intestinal tract. In October 1998, the Company received approval from the United States Food and Drug Administration (the "FDA") for its lead product Renagel(R)\* Capsules (sevelamer hydrochloride).

Additionally, throughout 1998, the Company continued its product development efforts focused on therapeutic agents for the treatment of hypercholesterolemia (elevated LDL cholesterol levels); obesity; and infectious diseases.

## Recent Publications by GelTex Pharmaceuticals Incorporated:



- [Bile acid binding to sevelamer HCl.](#)

*BACKGROUND: Clinical studies have shown sevelamer HCl (Renagel) to be...*14th January, 2003  
GelTex Pharmaceuticals, Waltham, Massachusetts, USA.- *Kidney Int.* 2002 Aug;62(2):611-9. ([DOI Direct Link](#))

- [A phosphate binding assay for sevelamer hydrochloride by ion chromatography.](#)

*Sevelamer hydrochloride is a cross-linked polymeric amine; it is the...*25th March, 2000  
GelTex Pharmaceuticals, Waltham, MA 02154, USA. [www.geltext.com](http://www.geltext.com).- *J Pharm Biomed Anal.* 1999 May;19(6):911-5.

## Press Releases on GelTex Pharmaceuticals Incorporated:

<a href="#">H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics</a>	20th November, 2009	Quest Diagnostics Incorporated	-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com
<a href="#">Reportlinker Adds Imaging Agents - A Worldwide Market Review</a>	20th November, 2009	Reportlinker	announces that a new market research report is available in its catalogue. Imaging Agents - A Worldwide Market Review http://www.reportlinker.com
<a href="#">AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured</a>	20th November, 2009	AstraZeneca	WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at a press conference at Philadelphia Health Care Center #6
<a href="#">Impax Laboratories Drives Stronger Performance with IBM Business Analytics</a>	20th November, 2009	IBM	-- C-level Executive Committee can now easily pull together a single view of net sales, profitability and competitive market share information, helping them to determine whether
<a href="#">New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)</a>	20th November, 2009	Quest Diagnostics Incorporated	MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,

## BioNews Results for GelTex Pharmaceuticals Incorporated



- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer](#)  
*FinanzNachrichten.de: Nov 16 2009 12:34AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)  
*Washington Business Journal: Nov 16 2009 1:25AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to](#)

[Discuss Resu](#)

*St Louis Business Journal: Nov 16 2009 12:45AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*San Jose Business Journal: Nov 16 2009 12:35AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*Reuters: Nov 16 2009 12:43AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*Globe Investor: Nov 16 2009 12:36AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*StockHouse USA: Nov 16 2009 12:22AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

*TradingMarkets: Nov 16 2009 12:18AM Matching: pharmaceuticals*

- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer](#)

*Stockwatch: Nov 16 2009 12:15AM Matching: pharmaceuticals*

- [Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor\(R\) i](#)

*Pharmacy Choice: Nov 15 2009 2:33PM Matching: pharmaceuticals*

- [Watson Announces Presentation Time Change at Credit Suisse Healthcare Conference](#)

*PharmiWeb: Nov 15 2009 3:25AM Matching: pharmaceuticals*

- [LecTec Corporation and Endo Pharmaceuticals Inc. Settle Patent Dispute](#)

*Pharma Live: Nov 14 2009 12:09PM Matching: pharmaceuticals*

- [Avalon Pharmaceuticals, Inc. - Financial And Strategic Analysis Review - New Report Published](#)

*OfficialSpin: Nov 14 2009 9:12AM Matching: pharmaceuticals*

- [Spectrum Pharmaceuticals and Nippon Kayaku Collaborate to Develop Apaziquone in Asia](#)

*TradingMarkets: Nov 14 2009 5:24AM Matching: pharmaceuticals*

- [LecTec and Endo Pharmaceuticals settle patent lawsuit](#)

*Pharmacy Choice: Nov 14 2009 12:59AM Matching: pharmaceuticals*

**GelTex Pharmaceuticals Incorporated Patents:**



- 5917007- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 6083497- [Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers](#)
- 6129910- [Water-insoluble noncrosslinked bile acid sequestrants](#)
- 6177478- [Method for reducing oxalate](#)
- 6187762- [Polyvalent polymers for the treatment of rotavirus infection](#)
- 6190649- [Polyether-based bile acid sequestrants](#)
- 6203785- [Poly\(diallylamine\)-based bile acid sequestrants](#)
- 6225355- [Process for removing bile salts from a patient and alkylated compositions therefor](#)

- 6235720- [Acid-functionalized saccharide polymers](#)
- 6248318- [Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers](#)
- 6264937- [Fat-binding polymers](#)
- 6083495- [Method of making phosphate-binding polymers for oral administration](#)
- 6066678- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 6060517- [Process for removing bile salts from a patient and compositions therefor](#)
- 5919832- [Amine polymer sequestrant and method of cholesterol depletion](#)
- 5925379- [Interpenetrating polymer networks for sequestration of bile acids](#)
- 5929184- [Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants](#)
- 5939537- [Acid-functionalized saccharide monomers](#)
- 5969090- [Hydrophobic sequestrant for cholesterol depletion](#)
- 5981693- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 5985938- [Method for reducing oxalate](#)
- 6007803- [Ionic polymers as toxin binding agents](#)
- 6034129- [Ionic polymers as anti-infective agents](#)
- 6060235- [Antiviral polymers comprising acid functional groups and hydrophobic groups](#)
- 6264938- [Combination therapy for treating hypercholesterolemia](#)
- 6267952- [Lipase inhibiting polymers](#)
- 6482402- [Antimicrobial compositions and methods](#)
- 6509013- [Method of making phosphate-binding polymers for oral administration](#)
- 6517825- [Polyether-based bile acid sequestrants](#)
- 6517826- [Anionic polymers as toxin binders and antibacterial agents](#)
- 6517827- [Anionic polymers as toxin binders and antibacterial agent](#)
- 6558657- [Lipase inhibiting polymers](#)
- 6565895- [Bismuth compounds for the treatment and prevention of mucositis](#)
- 6566407- [Method for reducing oxalate](#)
- 6572850- [Lipase inhibiting polymers](#)
- 6593366- [Ionic polymers as anti-infective agents](#)
- 6433026- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 6423754- [Method for treating hypercholesterolemia with polyallylamine polymers](#)
- 6419914- [Anionic polymers as toxin binders](#)
- 6268126- [Antiviral polymers comprising acid functional groups and hydrophobic groups](#)
- 6270755- [Anionic polymers as toxin binders](#)
- 6271264- [Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants](#)
- 6290946- [Anionic polymers as toxin binders and antibacterial agents](#)
- 6290947- [Ionic polymers as toxin-binding agents](#)
- 6294163- [Polymers containing guanidinium groups as bile acid sequestrants](#)
- 6299868- [Fat-binding polymers](#)
- 6352692- [Lipase inhibiting polymers](#)
- 6365186- [Combination therapy for treating hypercholesterolemia](#)
- 6395777- [Ionic polymers as anti-infective agents](#)
- 6646157- [Method for making HBED](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

